secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001453687-25-000077
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026
--------------------------------------------------------------------------------

- CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.
- Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.
- Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.
- No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/0001453687-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer